What antipsychotic medication has the least effect on appetite in a patient with significant appetite increase or weight gain due to antipsychotic therapy?

Antipsychotics with Least Effect on Appetite

Ziprasidone and lurasidone are the antipsychotics with the least effect on appetite and weight gain, followed closely by aripiprazole. 1, 2

Weight-Neutral Antipsychotic Options

The most weight-neutral antipsychotics, in order of preference, are:

• Ziprasidone and lurasidone demonstrate the lowest weight gain liability among all antipsychotics, with minimal effects on appetite and metabolic parameters 1, 2
• Aripiprazole is the next best option, showing generally lower risk for weight gain with mean weight change of only +0.3 kg in clinical trials 3
• In the landmark CATIE study, ziprasidone caused weight gain ≥7% in only 7% of patients, compared to 30% with olanzapine, 16% with quetiapine, 14% with risperidone, and 12% with perphenazine 4

Antipsychotics to Absolutely Avoid

When appetite increase or weight gain is a concern, never switch to olanzapine, clozapine, quetiapine, or risperidone as these cause substantially more weight gain than other options 1, 2:

• Clozapine and olanzapine produce the greatest weight gain, with olanzapine causing 30% of patients to gain ≥7% body weight and clozapine showing 35% with this degree of weight gain 5, 4
• Clozapine is associated with mean fasting triglyceride increases of 71 mg/dL (54%) and continued weight gain beyond the first year of treatment 5, 6
• Quetiapine and risperidone cause intermediate weight gain, with 16% and 14% of patients respectively gaining ≥7% body weight 4

Clinical Decision Algorithm

When managing a patient with antipsychotic-induced appetite increase or weight gain:

1. First, confirm the indication for continued antipsychotic therapy and assess whether switching is clinically appropriate based on symptom control 1

2. If switching is appropriate, prioritize ziprasidone or lurasidone as first-line alternatives, using gradual cross-titration to minimize symptom destabilization 1, 2

3. If switching is not clinically appropriate due to concerns about symptom control, offer metformin concomitantly (starting at 500 mg once daily, gradually increasing to 1g twice daily) to attenuate weight gain 2

4. Implement lifestyle interventions immediately including dietary counseling and physical activity recommendations for all patients 2

Important Caveats

• Aripiprazole shows favorable weight profiles in adults (mean +0.3 kg vs -0.1 kg placebo), but pediatric patients show more substantial weight gain (+1.6 kg vs +0.3 kg placebo at 6 weeks, and +5.8 kg vs +1.4 kg at 24 weeks) 3
• Antipsychotic-naive patients experience greater weight gain than patients switching from another antipsychotic, regardless of psychiatric diagnosis 7
• Weight gain with atypical antipsychotics may be extreme and represents the most common significant problem associated with their use, particularly in pediatric populations 8
• The classification of first-generation versus second-generation antipsychotics should not guide choice; focus instead on specific agent pharmacodynamic profiles 1

Monitoring Requirements

• Obtain baseline measurements of BMI, waist circumference, blood pressure, HbA1c, glucose, and lipids before starting any antipsychotic 2
• Monitor weight weekly for the first 6 weeks after starting or switching antipsychotics 2
• Recheck fasting glucose at 4 weeks after initiation, then repeat all baseline measurements at 3 months and annually thereafter 2